10-K/A: Interpace Biosciences Files Amendment to 10-K to Include Omitted Information

Interpace Biosciences files an amendment to its 2024 Annual Report on Form 10-K to include information that was to be incorporated by reference from the company's definitive proxy statement.

Summary

• Interpace Biosciences filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The amendment includes information that was to be incorporated by reference from the company's definitive proxy statement for its 2025 Annual Meeting of Stockholders.
• The proxy statement will not be filed within 120 days after the end of the company's fiscal year.
• The amendment restates Items 10, 11, 12, 13, and 14 of Part III and Part IV of the original filing.
• The document includes certifications required of the principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002.
• As of April 15, 2025, 4,414,904 shares of the company's common stock were issued and outstanding.
• The aggregate market value of the registrant's common stock held by non-affiliates on June 30, 2024, was $3,999,609.
• The Board of Directors currently consists of five members: Vijay Aggarwal, Thomas W. Burnell, Joseph Keegan, Fortunato Ron Rocca, and Stephen J. Sullivan.
• Executive officers include Thomas W. Burnell (President, CEO, and Chairman) and Christopher McCarthy (CFO).
• The company has adopted a written Code of Business Conduct and an Insider Trading Policy.
• The Audit Committee is comprised of Dr. Keegan (Chairperson), Mr. Sullivan and Mr. Rocca.
• The Compensation Committee is comprised of Mr. Sullivan (Chairperson) and Mr. Rocca.
• The Nominating Committee is comprised of Dr. Keegan (Chairperson), Dr. Aggarwal and Mr. Sullivan.
• The Regulatory Compliance Committee is comprised of Dr. Aggarwal (Chairperson), Dr. Keegan and Mr. Rocca.
• For fiscal year 2024, Mr. Burnell's annual base salary was $456,458, and he received a bonus of $184,250.
• For fiscal year 2024, Mr. McCarthy's annual base salary was $274,583, and he received a bonus of $110,000.
• Ampersand 2018 Limited Partnership beneficially owns 75.8% of the company's outstanding common stock as of April 15, 2025.
• 1315 Capital II, L.P. beneficially owns 68.1% of the company's outstanding common stock as of April 15, 2025.
• EisnerAmper LLP served as the company's independent accountants, with audit fees of $368,550 in 2024 and $268,275 in 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document is primarily a compliance filing. The need for an amendment introduces a slightly negative aspect, but the overall tone is factual and objective.

Positives

• The company is taking corrective action to ensure compliance with SEC reporting requirements by filing the amendment.
• The company has established key committees (Audit, Compensation, Nominating, and Regulatory Compliance) with independent directors.
• The company has a Code of Business Conduct and an Insider Trading Policy in place.

Negatives

• The need to file an amendment indicates a deficiency in the original filing process.
• The definitive proxy statement was not filed within the required timeframe.

Risks

• Failure to maintain compliance with SEC regulations could result in penalties or other adverse consequences.
• The high concentration of ownership by Ampersand and 1315 Capital could potentially influence company decisions.

Future Outlook

The document does not contain specific forward-looking statements regarding future financial performance or operational guidance.

Industry Context

This filing is a routine amendment to a standard SEC form, ensuring compliance with regulatory requirements. It does not provide specific insights into the company's competitive position or industry trends.

Key Dates

Keywords

Form 10-K/A, amendment, Interpace Biosciences, corporate governance, executive compensation, beneficial ownership, audit fees, directors, executive officers, SEC filing